Search Results - "Pulido, M Valderrey"

4CPS-106 Analysis of the prescription and safe drug administration of ocrelizumab by García Soler, JI, Arocas Casañ, V, Menendez Naranjo, L, Gonzalez Lozano, E, Laorden Carrasco, A, Diaz Ramon, M, Cano Molina, JA, Ramirez Roig, C, Valderrey Pulido, M, Vicente Sánchez, S

“…Background and importanceOcrelizumab is the first drug approved in Europe for the treatment of primary progressive multiple sclerosis (PPMS). It is an…”
Get full text

4CPS-054 Early levels of vancomycin in intensive care unit (icu) protocol depending on icu patients’ characteristics by Pulido, M Valderrey, Sanchez, S Vicente, Vera, APareja Rodriguez de, Jimenez, ROlmos, Jimenez, MDMRuiz, Gómez, ARuiz, Nieto, A de la Rubia

“…BackgroundEfficacy of vancomycin in critical ill patients is highly related with adequate vancomycin blood levels, so a vancomycin protocol has been developed…”
Get full text

DI-019 Efectiveness and safety of new antivirals agents in hiv patients with chronic hepatitis C by Naranjo, L Menendez, Luiz, A Tomas, Sánchez, S Vicente, Pulido, M Valderrey, Rivadeneyra, M Almanchel, Garre, M Sánchez

“…BackgroundThe development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment, particularly in…”
Get full text

DI-022 Use and clinical experience of DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA in a tertiary hospital by Sanchez, S Vicente, Naranjo, L Menendez, Pulido, M Valderrey, Jimenez, MDM Ruiz, Soler, JI Garcia, de la Rubia Nieto, MA

“…BackgroundThe new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.PurposeTo…”
Get full text

PP-021 Quality study of intravenous mixtures after the implementation of double check by Sánchez, S Vicente, Molina, O García, Pulido, M Valderrey, Contreras, MC Muñoz, Carmona, J Mateo, Nieto, A de La Rubia

“…BackgroundAvoiding errors related to drug development, which can compromise the patient’s life, is essential in our profession.PurposeTo describe the quality…”
Get full text

CP-091 Analysis of off-label use of levosimendan in paediatrics by Carmona, J Mateo, Molina, O García, Casañ, V Arocas, Espinosa, MA Fernández De Palencia, Pulido, M Valderrey, Sánchez, S Vicente, Luiz, A Tomás, Jiménez, MM Ruiz, Murie, P De La Cruz, Rueda, M Galindo

“…BackgroundLevosimendan is a calcium sensitising inodilator agent that is indicated for the short term treatment of severe acute decompensation of chronic heart…”
Get full text